

## Policy Statement; Prescribing of Dapoxetine for premature ejaculation is not supported

**Mid-Essex Clinical Commissioning Group does not support the prescribing of Dapoxetine (Priligy®) for treatment of premature ejaculation.**

**Dapoxetine** is a short-acting selective serotonin re-uptake inhibitor licensed for use in the treatment of premature ejaculation in men who meet all the following criteria: poor control over ejaculation, a history of premature ejaculation over the past 6 months, marked distress or interpersonal difficulty as a consequence of premature ejaculation, and an intravaginal ejaculatory latency time of less than two minutes.

The East of England Priorities Advisory Committee has advised that commissioning of Dapoxetine is low priority and is not recommended.

[PAC guidance](#) March 2014.

Providers commissioned to provide services on behalf of Mid-Essex CCG are reminded that they are required to follow the Mid-Essex CCG formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification).

See Mid-Essex CCG website – Medicines optimisation page for all prescribing guidance.

<http://midessexccg.nhs.uk/your-health-services/medicines-optimisation>

Title	<b>Dapoxetine for Premature Ejaculation</b>
Document reference	DapoxetinePOL201502V2.0FINAL
Author	Medicines Optimisation Team, Mid Essex CCG
Reference:	East of England Priorities Advisory Committee- Guidance statement on dapoxetine, March 2014 v 1 accessed via <a href="http://www.prescripp.info">www.prescripp.info</a>
Approved by	Mid Essex Medicines Management Committee Chair:Donald McGeachy
Date approved	February 2015
Next review date	February 2020

Previous version	Key Changes
November 2013	Format and reference link